Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002080 · ClinicalTrials.gov registry record · NA

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

A NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002080: Completed NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

NCT00002080 is a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by Pharmacia. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002080, a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by Pharmacia.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or \< 200.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Interventions

  • DRUG Rifabutin

Study Locations (1)

Pennsylvania

  • PACT - Saint Davids

Trial Details

FieldValue
Phase NA
Pharmacia

7 total trials

What the finished NCT00002080 record still lists

NCT00002080 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Rifabutin is the first listed.

NCT00002080 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00002080 about?

NCT00002080 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study". Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin. Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients...

What is the current status of trial NCT00002080?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002080 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

What interventions are being tested in trial NCT00002080?

The interventions under investigation include: Rifabutin (DRUG).

Who is sponsoring clinical trial NCT00002080?

This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002080 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002080, the US trial registry maintained by the National Library of Medicine. NCT00002080 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.